Fig. 4
From: Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
Vascular effects of nilotinib in human pulmonary vessels. a Nilotinib in naïve PAs/PVs (⃝) PA (n = 5); (□) PV (n = 6). b Effect of increasing concentration of nilotinib in pre-constricted PAs: (⃝) 100 nM ET-1 (n = 7); (●) 100 nM ET-1 / imatinib (n = 10). c Effect of increasing concentration of nilotinib in pre-constricted PVs: (□) 50 nM ET-1 (n = 6); (■) 50 nM ET-1 / imatinib (n = 8). b EC50 value was calculated using the standard 4-paramter logistic non-linear regression model. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001